SANTA MONICA, Calif.–(BUSINESS WIRE)–Activision Blizzard, Inc. (Nasdaq: ATVI) today announced that it convened its 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”) as scheduled and considered all items of business with the exception of Proposal 2, the shareholder advisory vote on executive compensation (the “Proposal”).
At the 2021 Annual Meeting held today, 86.54% of the Company’s outstanding shares were represented in person or by proxy. Of the matters presented for shareholder vote: all ten nominees for director were re-elected, with an average of 96.27% of the votes cast in favor; and on the appointment of PwC as the Company’s independent registered public accounting firm, 97.13% of the votes were cast in favor.
Based on requests from shareholders for additional time, the independent members of the Activision Blizzard Board believe it is in the best interest of its shareholders to extend the opportunity for shareholders to vote on this important matter, and therefore recommended an adjournment to allow additional time for shareholders to submit proxies with respect to the Proposal. The 2021 Annual Meeting will be reconvened on Monday, June 21, 2021 at 9:00 a.m. Pacific Time (the “Reconvened Annual Meeting”). The sole matter of business before the Reconvened Annual Meeting will be the Proposal.
The independent members of the Activision Blizzard Board have determined, based on requests from shareholders, that it is necessary and appropriate to leave voting for the Proposal open in order to provide shareholders with adequate time to review and consider the Company’s recent responses to statements that were published and recirculated about the Company’s executive compensation practices that the Company believed to be misleading, in particular related to CEO and COO compensation. The Board members believe that obtaining informed shareholder feedback related to Activision Blizzard’s compensation policies and practices is of fundamental importance, and therefore, allowing additional time for shareholders to meaningfully participate in the vote better represents their interests.
The Company’s recent responses highlighted the following points and corrections:
Activision Blizzard will continue to solicit proxies from shareholders with respect to the Proposal, and electronic voting platforms are expected to remain open. The Board recommends that shareholders vote “FOR” the Proposal and approve the Company’s executive compensation. The record date for determining shareholders eligible to vote on the Proposal remains April 19, 2021.
Activision Blizzard encourages any eligible shareholder that has not yet voted their shares or provided voting instructions to their broker or other record holders to do so promptly. If a shareholder has previously submitted its proxy and does not wish to change its vote, no further action is required. Shareholders who need help voting their shares may call Activision Blizzard’s proxy solicitor, Alliance Advisors, at (855) 928-4492.
Activision Blizzard expects to file the voting results regarding the other proposals considered today at the 2021 Annual Meeting on a Form 8-K with the Securities and Exchange Commission no later than June 18, 2021.
About Activision Blizzard
Our mission, to connect and engage the world through epic entertainment has never been more important. Through communities rooted in our video game franchises we enable hundreds of millions of people to experience joy, thrill and achievement. We enable social connections through the lens of fun, and we foster purpose and a sense of accomplishment through healthy competition. Like sport, but with greater accessibility, our players can find purpose and meaning through competitive gaming. Video games, unlike any other social or entertainment media, have the ability to break down the barriers that can inhibit tolerance and understanding. Celebrating differences is at the core of our culture and ensures we can create games for players of diverse backgrounds in the 190 countries our games are played.
As a member of the Fortune 500 and as a component company of the S&P 500, we have an extraordinary track record of delivering superior shareholder returns for over 30 years.
Our enduring franchises are some of the world’s most popular, including Call of Duty®, Crash Bandicoot™, World of Warcraft®, Overwatch®, Hearthstone®, Diablo®, StarCraft®, Candy Crush™, Bubble Witch™, Pet Rescue™ and Farm Heroes™. Our sustained success has enabled the company to support corporate social responsibility initiatives that are directly tied to our franchises. As an example, our Call of Duty Endowment has helped find employment for over 80,000 veterans.
Learn more information about Activision Blizzard and how we connect and engage the world through epic entertainment on the company’s website, www.activisionblizzard.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT
NORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. (‘Elite’ or the “Company’)(OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2021 (“Fiscal 2021”).
Consolidated revenues for Fiscal 2021 were $25.4 million, an increase of $7.4 million or approximately 41% from the comparable period of the prior fiscal year. The increase in revenues was primarily attributed to revenues from generic immediate-release Adderall®, generic extended-release Adderall®, generic Dantrolene Capsules, and strong revenues relating to Isradipine sales capsules. Operating profits were $2.1 million, an increase of $4.3 million from the comparable period of the prior year, and net income was $5.1 million.
Conference Call Information
Elite’s management will host a conference call to discuss the year-end 2021 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
The financial statements can be viewed for Elite’s Fiscal Year 2021 on Form 10-K here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, TAGI Pharma, and Glenmark Pharmaceuticals, Inc. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Elite Pharmaceuticals, Inc.
The stock price of Sorrento Therapeutics Inc (NASDAQ: SRNE) increased by 6.65% today. Investors responded positively to Sorrento Therapeutics announcing that the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom’s regulatory agency, cleared Sorrento’s COVI-DROPS product candidate for a Phase 2 efficacy trial.
The application was submitted as a rolling application and the MHRA cleared the study in under a month from Sorrento’s first submission to the MHRA. And the application was supported by the safety data from a healthy subject study completed in the US — which showed a safety profile comparable to placebo with doses up to 60 mg. In the study, there were no serious adverse effects or dose-limiting toxicities and all adverse effects were mild in severity. The maximum tolerated dose was not reached.
The Phase 2 efficacy trial is a large double-blind clinical trial enrolling 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms in a 2:2:1 randomization with patients receiving 10mg, 20mg, or placebo. This trial complements the Phase 2 trial currently being started in the US and a separate trial to be started in Mexico.
COVI-DROPS are administered as an intranasal instillation in each nares to recently infected patients and utilize the same neutralizing antibody drug substance as COVI-AMG (the intravenous formulation). And the antibody is active against the original SARS-CoV-2 virus as well as the most prevalent viral variants of concern (VoCs) currently infecting the UK and the US. These variants include the UK (Alpha) and the India (Delta) variants of concern.
The results of the Phase 2 trial in the UK will be combined with the results of the US and Mexico Phase 2 trials. And if the results of these studies demonstrate that COVI-DROPS is both safe and effective against SARS-CoV-2, then Sorrento will apply for Emergency Use Authorization in the US, India, UK, Mexico and European Union as well as other territories.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
DENVER–(BUSINESS WIRE)–Ping Identity Holding Corp. (NYSE: PING) (“Ping Identity”), the Intelligent Identity solution for the enterprise, today announced the commencement of an underwritten public offering of 6,000,000 shares of common stock by investment funds affiliated with Vista Equity Partners. Such selling stockholders will also grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of Ping Identity’s common stock. Ping Identity will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than underwriting discounts and commissions.
Morgan Stanley is acting as sole underwriter for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and has become effective. The proposed offering will be made only by means of a prospectus and a free writing prospectus. A copy of the prospectus and the free writing prospectus relating to this offering may be obtained, when available, by visiting the SEC’s website at www.sec.gov. Alternatively, the prospectus and the free writing prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Ping Identity’s current intentions, expectations or beliefs regarding the proposed common stock offering. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning. Forward-looking statements include all statements that are not historical facts. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. There is no assurance that any forward-looking statements will materialize. You are cautioned not to place undue reliance on forward-looking statements, which reflect expectations only as of this date. Ping Identity does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise.
About Ping Identity
Ping Identity is the Intelligent Identity solution for the enterprise. We enable companies to achieve Zero Trust identity-defined security and more personalized, streamlined user experiences. The Ping Intelligent Identity™ platform provides customers, workforce, and partners with access to cloud, mobile, SaaS and on-premises applications across the hybrid enterprise. Over half of the Fortune 100 choose us for our identity expertise, open standards, and partnerships with companies including Microsoft and Amazon. We provide flexible identity solutions that accelerate digital business initiatives, delight customers, and secure the enterprise through multi-factor authentication, single sign-on, access management, intelligent API security, directory, and data governance capabilities.
BETHESDA, Md., June 14, 2021 /PRNewswire/ — Centrus Energy Corp. (NYSE American: LEU) today announced that the U.S. Nuclear Regulatory Commission (NRC) approved the Company’s license amendment request to produce High-Assay, Low-Enriched Uranium (HALEU) at the Piketon, Ohio, enrichment facility. The Piketon plant is now the only U.S. facility licensed to enrich uranium up to 20 percent Uranium-235 (U-235) and expects to begin demonstrating HALEU production early next year.
“This approval is a major milestone in our contract with the Department of Energy,” said Daniel B. Poneman, Centrus President and CEO. “We appreciate the dedicated and rigorous work of the NRC staff and Commissioners in their review and approval of our license amendment request.”
HALEU-based fuels will be required for most of the advanced reactor designs currently under development and may also be utilized in next-generation fuels for the existing fleet of reactors in the United States and around the world. Developers of nine of the ten advanced reactor designs selected for funding under the Department of Energy’s Advanced Reactor Demonstration Program, including the two demonstration reactors, have said they will rely on HALEU-based fuels.
Under a 2019 contract with the U.S. Department of Energy’s Office of Nuclear Energy, Centrus is constructing a cascade of sixteen AC100M centrifuges – a U.S.-origin technology – to demonstrate production of HALEU. The three year, $115 million, cost-shared contract runs through mid-2022. The NRC license was granted for the period of the DOE contract. Centrus recently released an update on progress of construction for the demonstration cascade and anticipates completing performance under the contract in early 2022. If sufficient funding is provided to continue operation, the license can be amended to extend the term.
What is HALEU?
When uranium ore is extracted from the earth, the concentration of the fissile isotope uranium-235 is less than one percent. Most existing reactors in the United States and worldwide operate on Low-Enriched Uranium (LEU) fuel that has been enriched to a concentration of the U-235 isotope of slightly less than 5 percent. High-Assay Low-Enriched Uranium is further enriched so that the U-235 concentration is between 5 percent and 20 percent. While this is still far below the levels used to produce weapons or power U.S. Navy vessels, HALEU offers unique advantages as an advanced nuclear fuel for both existing and next generation reactors, including greater power density, improved reactor performance, fewer refueling outages, improved proliferation resistance, and smaller volumes of waste.
About Centrus Energy
Centrus Energy is a trusted supplier of nuclear fuel and services for the nuclear power industry. Centrus provides value to its utility customers through the reliability and diversity of its supply sources – helping them meet the growing need for clean, affordable, carbon-free electricity. Since 1998, the Company has provided its utility customers with more than 1,750 reactor years of fuel, which is equivalent to 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is also advancing the next generation of centrifuge technologies so that America can restore its domestic uranium enrichment capability in the future. Find out more at www.centrusenergy.com.
Forward Looking Statements:
This news release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. In this context, forward-looking statements mean statements related to future events, may address our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For Centrus Energy Corp., particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following, which may be amplified by the novel coronavirus (COVID-19) pandemic: risks related to natural and other disasters, including the continued impact of the March 2011 earthquake and tsunami in Japan on the nuclear industry and on our business, results of operations and prospects; the impact and potential extended duration of the current supply/demand imbalance in the market for low-enriched uranium (“LEU”); pricing trends and demand in the uranium and enrichment markets and their impact on our profitability; risks associated with our reliance on third-party suppliers to provide essential products and services to us; the impact of government regulation including by the U.S. Department of Energy (“DOE”) and the U.S. Nuclear Regulatory Commission; uncertainty regarding our ability to commercially deploy competitive enrichment technology; risks and uncertainties regarding funding for deployment of the American Centrifuge technology and our ability to perform and absorb costs under our agreement with DOE to demonstrate the capability to produce high assay low enriched uranium (“HALEU”) and our ability to obtain and/or perform under other agreements; risks relating to whether or when government or commercial demand for HALEU will materialize; the potential for further demobilization or termination of our American Centrifuge work; risks related to our ability to perform and receive timely payment under agreements with DOE or other government agencies, including risk and uncertainties related to the ongoing funding of the government and potential audits; the competitive bidding process associated with obtaining a federal contract; risks related to our ability to perform fixed-price and cost-share contracts, including the risk that costs could be higher than expected; risks that we will be unable to obtain new business opportunities or achieve market acceptance of our products and services or that products or services provided by others will render our products or services obsolete or noncompetitive; risks that we will not be able to timely complete the work that we are obligated to perform; failures or security breaches of our information technology systems; risks related to pandemics and other health crises, such as the global COVID-19 pandemic; the outcome of legal proceedings and other contingencies (including lawsuits and government investigations or audits); the competitive environment for our products and services; changes in the nuclear energy industry; the impact of financial market conditions on our business, liquidity, prospects, pension assets and insurance facilities; and other risks and uncertainties discussed in this and our other filings with the Securities and Exchange Commission, including under Part 1. Item1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and our quarterly reports on Form 10-Q.
These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this report and in our other filings with the Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that may affect our business. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this News Release, except as required by law.
Media: Lindsey Geisler, (301) 564-3392, [email protected]
SOURCE Centrus Energy Corp.
FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, are now available on Geron’s website as well as to participants of the EHA2021 Virtual Congress.
“These poster presentations further support imetelstat’s differentiated approach to potentially target the malignant stem and progenitor cells in the bone marrow by inhibiting telomerase activity,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer. “Through this novel mechanism of action, imetelstat has the potential to alter the course of MDS and MF which distinguishes it from other treatments currently approved or in development. We look forward to confirming these results in our ongoing Phase 3 clinical trials, IMerge Phase 3 in lower risk MDS and IMpactMF in refractory MF.”
Title: Efficacy of Imetelstat is Independent of Molecular Subtypes in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA)
Poster Code: EP910
New data and analyses were presented on the clinical efficacy of imetelstat in molecularly defined subtypes based on cytogenetic and mutation profiles for patients in the IMerge Phase 2 clinical trial. As reported at previous EHA meetings, meaningful and durable transfusion independence were observed in patients from IMerge Phase 2, including transfusion-free periods greater than one year, as well as substantial increases in hemoglobin. The current presentation reported clinical responses across different cytogenetic and molecularly defined categories whereby responses were independent of mutation status or number of mutations. These data support the unique telomerase inhibition mechanism of action of imetelstat and the potential to target the malignant stem and progenitor cells of the underlying disease.
Title: Imetelstat Demonstrates an Acceptable Safety Profile in Myeloid Malignancies
Poster Code: EP1106
Safety data from the Phase 2 IMbark and IMerge trials were further analyzed to understand the characteristics of hematologic and non-hematologic adverse events. These analyses highlighted that the imetelstat-related cytopenias are short, reversable and with limited clinical consequence when managed with the dose modification guidelines in the protocols. These data are further evidence for the on-target effect of imetelstat based on the selective reduction of malignant cells in the bone marrow through telomerase inhibition resulting in the observed meaningful clinical benefits for patients in the Phase 2 trials.
Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Data from Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis-stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) imetelstat’s potential to alter the course of MDS and MF; (ii) that imetelstat has potential disease-modifying activity; (iii) the potential of imetelstat to target the malignant stem and progenitor cells of the underlying disease; and (iv) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron overcomes all of the potential delays and other adverse impacts caused by the current or evolving effects of the COVID-19 pandemic, and overcomes all the enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges to complete its two Phase 3 clinical trials; (b) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (c) whether any future efficacy or safety results may cause the benefit-risk profile of imetelstat to become unacceptable; (d) whether imetelstat actually demonstrates disease-modifying activity in patients; and (e) whether imetelstat demonstrates that it targets the malignant stem and progenitor cells of the underlying disease in patients. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s quarterly report on Form 10-Q for the quarter ended March 31, 2021 and future filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
CLEVELAND, June 14, 2021 /PRNewswire/ — Avient Corporation (NYSE: AVNT), a premier provider of specialized and sustainable material solutions and services, has announced it is collaborating with Oceanworks® to help customers incorporate recycled ocean plastics in their products. Recycled ocean and ocean-bound plastics are those recovered from the ocean, waterways, and ocean-bound collection zones within 50 km of a coastline.
Building on the 2020 launch of reSound™ R recycled content thermoplastic elastomers (TPEs) created with Oceanworks recycled plastics, Avient and Oceanworks are now collaborating on an expanded recycled ocean plastics portfolio. The resulting custom-formulated materials – both TPEs and thermoplastics – will be based on Oceanworks Guaranteed* base resins. Oceanworks will also provide source validation so that brands can confidently and transparently share the story and impact of these materials.
Avient and Oceanworks initially connected through the Alliance to End Plastic Waste (AEPW). Avient is a founding member of AEPW, joining in 2019. Oceanworks was selected in 2020 as a breakthrough venture to be incubated under AEPW’s Innovation program with early-stage startup accelerator, Plug and Play.
“Expanding our collaboration with Oceanworks aligns closely with our sustainability commitments as a formulator and our focus on helping customers meet their sustainability goals,” said Walter Ripple, Vice President, Sustainability, Avient Corporation. “Oceanworks maintains the largest global marketplace for recycled ocean plastics and brings knowledge and capability that are invaluable to building this new portfolio.”
“As a leading global polymer material formulation expert, Avient will help us to further extend the usage of recycled ocean plastics to specialty formulations and applications,” said Rob Ianelli, Founder and President at Oceanworks. “Their global customers represent a wide range of end markets that value the addition of recycled ocean plastics. Every ton of at-risk plastic waste successfully averted on its path to the ocean is part of the solution. We are thrilled to have the opportunity to drive further customization and scale in collaboration with Avient.”
“Customers want to utilize recycled ocean plastics, but many times don’t know how to source or evaluate it,” Mr. Ripple explained. “Through this new collaboration, customers now can incorporate recycled ocean plastics solutions to help them achieve both performance and sustainability goals.”
Avient’s solutions with Oceanworks’ recycled ocean plastics content are available globally and can be utilized in a variety of TPE and engineered thermoplastic formulations.
*Oceanworks® Guaranteed materials are independently validated. Oceanworks conducts third-party testing through its laboratory partners to confirm resins are contamination free and processing parameters are met. The Oceanworks Guaranteed mark indicates that the material meets specifications and has been sourced in compliance with international standards for business, environmental, and fair labor practices. Traceability is ensured with Oceanworks Guaranteed material and transaction certificates for each order.
Oceanworks® is a digital marketplace connecting local recycled plastic supply with global demand to keep plastic out of the ocean. The marketplace offers 100s of ocean and averted plastic resins, textiles, and products from trusted suppliers worldwide. Oceanworks quality standards allow customers to purchase with confidence and the capacity of the global network provides security at scale. Customers, brands and suppliers that use the Oceanworks® Guarantee become part of a larger solution – a circular economy to end ocean plastic. To learn more visit oceanworks.co.
Avient Corporation (NYSE: AVNT), with expected 2021 revenues of $4.3 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world. Examples include:
Avient employs approximately 8,400 associates and is certified ACC Responsible Care®, a founding member of the Alliance to End Plastic Waste and certified Great Place to Work®. For more information, visit www.avient.com.
To access Avient’s news library online, please visit www.avient.com/news.
SOURCE Avient Corporation
The stock price of Marathon Digital Holdings Inc (NASDAQ: MARA) increased by over 13% during intraday trading. Investors are responding positively to the increase in the price of bitcoin.
Marathon Digital is known as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets. The increase in bitcoin price was driven by statements by recent statements by Tesla CEO Elon Musk and hedge fund executive Paul Tudor Jones.
In an interview with CNBC, Jones said: “I like bitcoin as a portfolio diversifier. Everybody asks me ‘what should I do with my bitcoin?’ The only thing I know for certain, I want 5% in gold, 5% in bitcoin, 5% in cash, 5% in commodities. At this point in time, I don’t know what I want to do with the other 80% until I see what the Fed is going to do.”
And Tesla CEO Elon Musk disclosed that the electric vehicle company will accept bitcoin again when there is confirmation of reasonable clean energy usage by the cryptocurrency miners. Below is the tweet:
This is inaccurate. Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market.
When there’s confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions.
— Elon Musk (@elonmusk) June 13, 2021
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
The shares of Lordstown Motors Corp (NASDAQ: RIDE) have received a price target decrease from $9 to $3 by R.F. Lafferty. And R.F. Lafferty analyst Jaime Perez had downgraded Lordstown Motors from a previous “Hold” rating to a “Sell” rating.
Perez noted that the downgrade is due to the company’s announcement that CEO Steve Burns and CFO Julio Rodriguez had resigned. Perez pointed out that Lordstown had warned of a going concern risk and during the company’s first-quarter earnings call, the company said it might need to raise more capital to meet its production forecast.
Perez believes that a downgrade to “Sell” was necessary with the level of “uncertainty increasing in the future.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.